Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for nonsquamous programmed death-ligand 1-High (≥50%) NSCLC in the German national network genomic medicine lung cancer - Bischoff, Philip; Reck, Martin; Overbeck, Tobias; Christopoulos, Petros; Röper, Julia; Janning, Melanie; Stenzinger, Albrecht; Griesinger, Frank; Thomas, Michael (Journal of thoracic oncology, 2024)
Online verfügbar: 13. Dezember 2024, Artikelversion: 6. Mai 2024